Michael Burkes Brophy Sells 1,863 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 1,863 shares of the firm’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $249.38, for a total value of $464,594.94. Following the completion of the transaction, the chief financial officer owned 52,432 shares in the company, valued at $13,075,492.16. This represents a 3.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, July 28th, Michael Burkes Brophy sold 2,419 shares of Natera stock. The shares were sold at an average price of $253.96, for a total value of $614,329.24.
• On Monday, July 27th, Michael Burkes Brophy sold 782 shares of Natera stock. The shares were sold at an average price of $260.49, for a total value of $203,703.18.
• On Monday, May 4th, Michael Burkes Brophy sold 482 shares of Natera stock. The stock was sold at an average price of $210.49, for a total value of $101,456.18.
• On Friday, May 1st, Michael Burkes Brophy sold 313 shares of Natera stock. The shares were sold at an average price of $206.16, for a total value of $64,528.08.

Natera Trading Up 0.6%

Shares of NTRA stock traded up $1.60 on Wednesday, reaching $253.82. The company had a trading volume of 925,147 shares, compared to its average volume of 1,091,572. The stock has a market cap of $36.35 billion, a PE ratio of -155.72 and a beta of 1.51. The company has a 50-day moving average of $244.16 and a 200-day moving average of $221.65. Natera, Inc. has a 12 month low of $131.81 and a 12 month high of $288.04.

Analyst Ratings Changes

Several equities research analysts have commented on NTRA shares. UBS Group set a $260.00 target price on shares of Natera in a research note on Wednesday, June 24th. Wall Street Zen cut shares of Natera from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Sanford C. Bernstein initiated coverage on shares of Natera in a report on Friday, June 26th. They issued an “outperform” rating and a $310.00 price target for the company. Wells Fargo & Company lifted their target price on Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. Finally, Royal Bank Of Canada initiated coverage on Natera in a research report on Thursday, June 11th. They set an “outperform” rating and a $275.00 price target on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Natera presently has a consensus rating of “Moderate Buy” and a consensus price target of $267.83.

Hedge Funds Weigh In On Natera

A number of large investors have recently added to or reduced their stakes in NTRA. Reflection Asset Management acquired a new stake in shares of Natera in the 4th quarter valued at approximately $29,000. Elevation Wealth Partners LLC bought a new position in shares of Natera in the 2nd quarter valued at about $30,000. Palladiem LLC acquired a new position in shares of Natera during the 4th quarter worth about $31,000. Horizon Investments LLC acquired a new position in shares of Natera during the 3rd quarter worth about $32,000. Finally, International Assets Investment Management LLC increased its stake in shares of Natera by 132.9% during the 1st quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after purchasing an additional 97 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.